Physician profile
Clive Gomilla
NPI 1568047249
$9,215.37
in general payments reported to CMS, 2019-2025
33 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $611 · 2022: $1,831 · 2023: $2,377 · 2024: $2,711 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,673 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,673.06 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,198.44 | 2022-2025 | Watchman Flx, Watchman Access System, Varithena Administration Pack |
| Merck Sharp & Dohme LLC | $1,085.56 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $863.97 | 2022-2025 | |
| Impulse Dynamics (USA) INC. | $839.56 | 2022-2024 | Optimizer, Optimizer |
| Astrazeneca Pharmaceuticals LP | $618.70 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Novo Nordisk INC | $610.08 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $526.18 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $491.74 | 2021-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $397.79 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $370.22 | 2021-2025 | Nexletol |
| Bridgebio Pharma, INC. | $344.29 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $295.91 | 2021-2025 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $244.21 | 2023 | Uptravi, Opsumit |
| Medtronic, INC. | $240.80 | 2021-2025 | Corevalve Evolut R, Harmony |
| Alnylam Pharmaceuticals INC. | $165.10 | 2022-2024 | Onpattro, Amvuttra |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $130.72 | 2021-2024 | Carto 3 |
| Amgen INC. | $124.00 | 2021-2024 | Repatha |
| Nevro Corp. | $114.82 | 2021 | |
| Inspire Medical Systems, INC. | $91.28 | 2025 | Inspire |
| Azurity Pharmaceuticals, INC. | $71.89 | 2023-2024 | Edarbyclor, Edarbyclor |
| Edwards Lifesciences Corporation | $47.54 | 2023-2025 | Sapien 3 Ultra Resilia |
| Medline Industries LP | $44.51 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.96 | 2021-2024 | Lifevest |
| Ge Healthcare | $32.69 | 2025 | |
| Kestra Medical Technology Services, INC. | $31.03 | 2025 | Assure Wcd |
| Cashflow Solutions, LLC | $30.33 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Sanofi-Aventis U.S. LLC | $29.07 | 2022 | |
| Angiodynamics, INC. | $27.45 | 2024 | Alphavac |
| Pfizer INC. | $27.36 | 2024 | |
| Atricure, INC. | $25.96 | 2025 | Atriclip Laa Exclusion System |
| Amarin Pharma, INC. | $22.67 | 2022 | |
| Altathera Pharmaceuticals LLC | $18.85 | 2022 | |
| Scpharmaceuticals INC. | $12.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clive Gomilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.